Analytical Data
-
基因名
CEACAM3
- Application
-
别名
CD66d; CEA; CD66-D; CGM1; W264; W282; Carcinoembryonic antigen CGM1
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 97% as determined by reducing SDS-PAGE.
-
蛋白编号
P40198
-
表达区间
Lys35~Glu190
-
分子量
18kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CEACAM3, or Carcinoembryonic Antigen-related Cell Adhesion Molecule 3, is a member of the CEACAM family of proteins, which are primarily involved in immune responses and cell adhesion processes. Research on CEACAM3 has gained traction due to its role as a receptor for certain pathogens, including Neisseria gonorrhoeae, and its implications in inflammatory responses and cancer biology. It is predominantly expressed on the surface of neutrophils, where it participates in the modulation of immune signaling pathways. The study of recombinant CEACAM3 proteins has provided valuable insights into its structural and functional characteristics, facilitating the understanding of its interactions with ligands and its role in host-pathogen interactions. Additionally, recombinant CEACAM3 is being explored for its potential applications in therapeutic interventions, including the development of vaccines and immune modulators. The ability to produce CEACAM3 in recombinant form allows for advanced studies, including crystallography and biochemical assays, which can elucidate its mechanism of action and pave the way for targeted therapies in infectious diseases and cancer. Overall, the ongoing research into CEACAM3 and its recombinant forms underscores its significance in immunology and pathology, offering promising avenues for novel therapeutic strategies.
